# US 2010/0168050 A1 · Compounds having antiangiogenic activity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168050 A1
- Document ID: US20100168050A1
- Status: Published application
- Kind: A1
- Application number: 12/626,356
- Filed: 2009-11-25
- Published: 2010-07-01
- Earliest claimed: 2004-02-17
- Assignees: Medestea Internazionale S.R.L.
- Inventors: Maria Elena FERRERO
- Web page: https://patentgrep.com/patent/US20100168050A1

## CPC

- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The use of o-ATP as a pharmacological agent useful for the treatment of diseases in whose onset or progression angiogenesis is involved.

## Claims

### Claim 1

A method for treating a tumor disease selected from lymphoma and leukemia in a subject in need thereof, said method comprising administering to said subject an effective amount of adenosine-5′-triphosphate-2′,3′-dialdehyde (oATP).

### Claim 2

A method for inhibiting vascular endothelial growth factor (VEGF)-induced cell proliferation of endothelial cells, comprising: administering to said endothelial cells an effective amount of adenosine-5′-triphosphate-2′,3′-dialdehyde (oATP).

### Claim 3 (depends on 2)

The method according to claim 2, wherein the endothelial cells are human endothelial cells.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the adenosine-5′-triphosphate-2′,3′-dialdehyde is administered in a pharmaceutical form selected from the group consisting of tablet, pill, capsule, granulate, powder, suppository, solution, spray, syrup, cream, ointment, gel, paste, lotion, emulsion and suspension.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the adenosine-5′-triphosphate-2′,3′-dialdehyde is administered in a daily dosage of 0.01 to 100 mg per Kg of body weight of said subject.
